{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-155477","form_type":"8-K","ticker":"TMDX","cik":"0001756262","company_name":"TransMedics Group, Inc.","filed_at":"2023-05-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.402472+00:00","generated_at":"2026-06-14T13:11:09.553111+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Shareholders approve amended equity plan, adding 1M shares and extending to 2033","bullets":["Plan amendment increases share reserve by 1,000,000 shares and extends expiration to June 1, 2033.","Directors elected: Waleed H. Hassanein, James R. Tobin, Edward M. Basile, Thomas J. Gunderson, Edwin M. Kania, Stephanie Lovell, Merilee Raines, David Weill.","Say-on-pay proposal approved with 22,963,086 votes for, 1,519,849 against.","Plan amendment approved with 19,996,361 votes for, 4,483,557 against.","Ratification of PricewaterhouseCoopers as auditor passed with 26,378,751 votes for."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-155477","json":"https://secwatch.observer/filing/0001193125-23-155477.json","markdown":"https://secwatch.observer/filing/0001193125-23-155477.md","text":"https://secwatch.observer/filing/0001193125-23-155477.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1756262/000119312523155477/0001193125-23-155477-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1756262/000119312523155477/d498391d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T13:11:09.553111+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5af0b146043ec0ffd02eca5cece3442351be9ed1","claim":"TransMedics Group, Inc. shareholders approved Approval of Amended and Restated TransMedics Group, Inc. 2019 Stock Incentive Plan at the 2023-05-25 meeting.","evidence_excerpt":"Proposal Three : The shareholders approved the Amended and Restated TransMedics Group, Inc. 2019 Stock Incentive Plan, based on the following votes: For Against Abstain Broker Non-Votes 19,996,361 4,483,557 21,292 2,433,153","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1756262/000119312523155477/0001193125-23-155477-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-25"}],"fact_type":"shareholder_vote"},{"claim_id":"76be72165b750b3ac3b9dfb13d4b92d7aa03868b","claim":"TransMedics Group, Inc. shareholders approved Election of eight directors to serve until the 2024 annual meeting at the 2023-05-25 meeting.","evidence_excerpt":"Proposal One : The shareholders elected Waleed H. Hassanein, M.D., James R. Tobin, Edward M. Basile, Thomas J. Gunderson, Edwin M. Kania, Stephanie Lovell, Merilee Raines and David Weill, M.D. as directors, each to serve on the board of directors of the Company until the 2024 annual meeting of the Company’s shareholders to be held in 2024 or until his or her successor is duly elected and qualified in accordance with our restated articles of organization and second amended and restated bylaws, or his or her earlier death, resignation or removal, based on the following votes: Director Nominee For Against Abstain Broker Non-Votes Waleed H. Hassanein, M.D 24,276,377 218,114 6,719 2,433,153 James R. Tobin 22,266,327 2,227,909 6,974 2,433,153 Edward M. Basile 19,270,950 5,222,893 7,367 2,433,153 Thomas J. Gunderson 24,375,647 118,498 7,065 2,433,153 Edwin M. Kania 24,144,520 349,634 7,056 2,433,153 Stephanie Lovell 23,196,175 1,298,370 6,665 2,433,153 Merilee Raines 24,372,323 122,126 6,761","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1756262/000119312523155477/0001193125-23-155477-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-25"}],"fact_type":"shareholder_vote"},{"claim_id":"899a21ef3cf54c14f0973aecdcc5974e6a4e59fb","claim":"TransMedics Group, Inc. shareholders approved Ratification of PricewaterhouseCoopers LLP as independent auditor for fiscal year ending December 31, 2023 at the 2023-05-25 meeting.","evidence_excerpt":"Proposal Four : The shareholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2023, based on the following votes: For Against Abstain 26,378,751 546,315 9,297","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1756262/000119312523155477/0001193125-23-155477-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-25"}],"fact_type":"shareholder_vote"},{"claim_id":"8a7971883dc1244895d5881f15aeee2e1d1c7b3c","claim":"TransMedics Group, Inc. shareholders approved Advisory vote on executive compensation at the 2023-05-25 meeting.","evidence_excerpt":"Proposal Two : The shareholders approved, on a non-binding advisory basis, the compensation paid to the Company’s named executive officers, based on the following votes: For Against Abstain Broker Non-Votes 22,963,086 1,519,849 18,275 2,433,153","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1756262/000119312523155477/0001193125-23-155477-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-25"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}